论文部分内容阅读
目的：探讨东菱迪芙联合银杏内酯B治疗急性脑梗死的疗效及安全性。方法急性脑梗死患者120例随机分为三组。东菱迪芙治疗组40例，静脉滴注1疗程(首日10BU/d，隔日5BU/d)；银杏内酯B治疗组40例，静脉滴注6ml/d；两药联合组40例，剂量同单药组。观察三组患者临床疗效、血浆纤维蛋白原水平及神经功能缺损评分变化。结果两药联合组显效率为77.5%明显高于东菱迪芙组55%和银杏内酯B组50%，差异有统计学意义(<0.05)。治疗后三组血浆纤维蛋白原水平及神经功能缺损程度评分均显著低于治疗前；与东菱迪芙组及银杏内酯B组相比，联合用药组血浆纤维蛋白原水平及神经功能缺损程度评分均显著降低，差异有统计学意义(均<0.05)。三组患者均无严重不良反应。结论急性脑梗死患者在常规用药基础上，应用东菱迪芙联合银杏内酯B治疗疗效更为显著，且安全性较好。“,”Objective To explore the ef icacy and safety of Batroxobin and ginkgolide B in acute cerebral infarction. Methods 120 cases of patients with acute cerebral infarction were randomly divided into three groups. Batroxobin treatment group 40 cases, a course of intravenous infusion (the first day of 10BU /d, every other day 5BU/d);Ginkgolide B treatment group 40 cases, intravenous 6ml/d;two-drug combination group 40 cases, the same dose as monotherapy group. To study the clinical ef icacy ,plasma fibrinogen levels and neurological function in three groups.Results The ef ective rate was significantly higher in the two-drug combination group 77.5%than Batroxobin group 55%and Ginkgolide group B 50%, the dif erence was statistical y significant ( <0.05). After treatment, the three groups of plasma fibrinogen levels and the degree of neurological deficit scores were significantly lower than before; compared with Batroxobin group and Ginkgolide group B, the combination of plasma fibrinogen levels and neurological deficit scores were significantly lower, the dif erence was statistical y significant ( <0.05). None of three groups had serious adverse reactions. Conclusion Based on the conventional therapy, combination of Batroxobin and ginkgolide B were more ef ective with bet er security in acute cerebral infarction patients.